Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:14 pm Purchase | 2024-09-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN | Armistice Capital, LLC | 5,096,000 9.250% | 446,000 (+9.59%) | Filing History |
| 2024-11-01 4:35 pm Sale | 2024-09-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN | Macquarie Group Limited | 2,631,897 4.780% | -105,824 (-3.87%) | Filing History |
| 2024-10-31 11:55 am Purchase | 2024-10-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | DIMENSIONAL FUND ADVISORS LP | 2,882,505 5.200% | 2,882,505 (New Position) | Filing History |
| 2024-02-14 2:33 pm Purchase | 2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | Armistice Capital, LLC | 4,650,000 8.510% | 294,000 (+6.75%) | Filing History |
| 2024-02-14 07:06 am Purchase | 2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | Macquarie Group Limited | 2,737,721 5.010% | 2,737,721 (New Position) | Filing History |
| 2024-02-13 5:15 pm Purchase | 2023-12-29 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 6,214,731 11.380% | 424,771 (+7.34%) | Filing History |
| 2024-01-19 2:40 pm Purchase | 2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 10,381,318 19.000% | 777,245 (+8.09%) | Filing History |
| 2023-02-14 1:33 pm Purchase | 2022-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | Armistice Capital, LLC | 4,356,000 8.060% | 220,000 (+5.32%) | Filing History |
| 2023-02-09 11:32 am Purchase | 2022-12-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 5,789,960 10.710% | 276,811 (+5.02%) | Filing History |
| 2023-01-23 3:52 pm Purchase | 2022-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 9,604,073 17.800% | 1,153,051 (+13.64%) | Filing History |
| 2022-02-14 7:03 pm Purchase | 2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | Armistice Capital, LLC | 4,136,000 7.800% | 1,016,000 (+32.56%) | Filing History |
| 2022-02-10 08:37 am Purchase | 2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 5,513,149 10.370% | 215,071 (+4.06%) | Filing History |
| 2022-01-27 5:14 pm Unchanged | 2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 8,451,022 15.900% | 0 (Unchanged) | Filing History |
| 2022-01-26 09:16 am Sale | 2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 8,451,022 15.900% | -461,779 (-5.18%) | Filing History |
| 2021-02-16 5:00 pm Purchase | 2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | Armistice Capital, LLC | 3,120,000 5.900% | 232,000 (+8.03%) | Filing History |
| 2021-02-10 11:57 am Sale | 2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 5,298,078 10.060% | -7,811 (-0.15%) | Filing History |
| 2021-01-25 4:50 pm Purchase | 2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 8,912,801 16.900% | 177,969 (+2.04%) | Filing History |
| 2020-03-12 5:13 pm Purchase | 2020-03-02 | 13G | Supernus Pharmaceuticals, Inc. SUPN | Armistice Capital, LLC | 2,888,000 5.500% | 2,888,000 (New Position) | Filing History |
| 2020-02-11 7:29 pm Purchase | 2019-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 5,305,889 10.110% | 67,827 (+1.29%) | Filing History |
| 2020-02-10 07:32 am Purchase | 2019-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 8,734,832 16.600% | 659,173 (+8.16%) | Filing History |